Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials

Curr Opin Virol. 2014 Dec:9:53-60. doi: 10.1016/j.coviro.2014.09.006. Epub 2014 Oct 4.

Abstract

Roseoloviruses frequently reactivate in transplant recipients. We review the impact of Roseoloviruses in transplant recipients and highlight research priorities. Human herpesvirus 6A (HHV-6A) and HHV-6B were recently classified as distinct species with important differences. Both viruses can result in inherited chromosomally integrated HHV-6, which may cause complications after transplant. HHV-6B is the primary species associated with disease and appears to have pleiotropic effects on the central nervous system. Small preemptive and prophylactic studies have not shown a statistically significant impact on HHV-6 disease. Although Roseoloviruses are associated with diverse complications in transplant patients, studies providing strong evidence for a causal role are lacking. Trials focusing on prevention and treatment will be important to inform the significance of Roseolovirus reactivation.

Publication types

  • Review

MeSH terms

  • Herpesvirus 6, Human / genetics
  • Herpesvirus 6, Human / physiology
  • Humans
  • Immunocompromised Host*
  • Roseolovirus Infections / epidemiology*
  • Roseolovirus Infections / pathology*
  • Transplant Recipients*
  • Virus Activation
  • Virus Integration